# hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis

> **NCT03826433** · PHASE1 · RECRUITING · sponsor: **Sclnow Biotechnology Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Peripheral iv

## Key facts

- **NCT ID:** NCT03826433
- **Lead sponsor:** Sclnow Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-10-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03826433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03826433, "hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03826433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*